Studying Vibroacoustic Lung Therapy for Older Adults with Respiratory Failure and Hip Fractures Using Different Device Modes

What this Trial Is About

This clinical trial investigates the course of acute respiratory failure in elderly patients with hip fractures by comparing different modes of a vibroacoustic device designed for the lungs. The study evaluates the use of the Vibrolung device, which produces a powerful vibroacoustic signal to treat and prevent respiratory complications, aiming to assess its effects on patients aged 60 to 85 who have respiratory failure and hip fractures. Participants will receive vibroacoustic pulmonary therapy using the Vibrolung device in one of two modes Pneumonia or Prevention. Treatment sessions will occur 4 to 6 times daily, each lasting about 5 minutes, over a 5-day period. The devices emitters are applied to affected lung areas, and the therapy is conducted by trained medical professionals, allowing for easy patient positioning without the need for active participation, which is particularly important for patients on ventilators or with limited mobility. During the study, arterial blood gases will be measured on the first day to assess treatment impact, and chest X-rays will also be taken. Blood samples will be collected, and the overall health status of participants will be monitored according to the Ministry of Health protocol. The study uses a randomized design with single masking, and the total participation period includes the 5-day treatment and follow-up assessments.

The Course of Acute Respiratory Failure in Geriatric Patients With Hip Fracture Using Different Modes of a Vibroacoustic Device for the Lungs